Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Bicycle Therapeutics Ltd.. (3/2/17). "Press Release: Bicycle Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference". Cambridge, MA & Cambridge.

Organisations Organisation Bicycle Therapeutics Ltd.
  Group Bicycle Therapeutics (Group)
  Organisation 2 Cowen & Company LLC
  Group Cowen (Group)
Products Product Cowen & Co. Annual Health Care Conference 2017 Boston
  Product 2 Bicycles® platform (bicyclic peptides)
Index terms Index term Bicycle Therapeutics–Cowen: investor conference, 201703 supply service Bicycle presents at Cowen & Co Annual Health Care Conference 2017
  Index term 2 Bicycle Therapeutics–Ten Bridge Communications: public relations, 201611 service existent by Ten Bridge
Persons Person Lee, Kevin (Bicycle Therapeutics 201509– CEO before Pfizer + GSK)
  Person 2 Sutton, Sarah (Ten Bridge Communications 201611 Director)

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (BicycleTM) product platform, announced today that Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will take place at 8:30 a.m. ET on Tuesday, March 7, 2017 in the MIT Room at the Boston Marriott Copley Place.

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other debilitating diseases based on its proprietary bicyclic peptide (BicycleTM) product platform. BicyclesTM exhibit an affinity and exquisite target specificity usually associated with antibodies, while a low molecular weight delivers rapid and deep tissue penetration enabling more efficient tumor targeting. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicities often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead molecule, BT1718, and is collaborating in oncology and other areas to realize the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit


Ten Bridge Communications (U.S.)
Sarah Sutton

Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan
+44 20 3709 5700

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Bicycle Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top